Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 1, 2006, Pages 70-75

  DiGianni, Lisa M ^a   Rue, Montserrat ^b   Emmons, Karen ^a   Garber, Judy E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b C Agy Hlth Technol Assess Res   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENE PRODUCT; HERBACEOUS AGENT;

ACUPUNCTURE; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; COPING BEHAVIOR; DISEASE COURSE; EXERCISE; FEMALE; FOLLOW UP; GENE FUNCTION; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASSAGE; MEDITATION; NUTRITIONAL SUPPORT; ONCOGENE; PATIENT SELECTION; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; YOGA; ATTITUDE TO HEALTH; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETIC SCREENING; GENETICS; HEALTH BEHAVIOR; MUTATION; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE; UTILIZATION REVIEW;

ADULT; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LINEAR MODELS; MUTATION; QUESTIONNAIRES;

EID: 33645456099     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0646     Document Type: Article

References (40)

1. Eisenberg D, Kessler R, Foster C, Kronenberg F. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993;328(4):246-52.
2. Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med 1998;129(12):1061-5.
3. Eisenberg D, Davis R, Ettner S, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280(18):1569-75.
4. National Center for Complementary and Alternative Medicine, Department of Health and Human Services, National Institutes of Health. Expanding horizons of healthcare: five-year strategic plan 2001-2005; 2000.
5. Crocetti E, Crotti N, Feltrin A, et al. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 1998; 34(3):324-8.
6. Boon H, Stewart M, Kennard MA, et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000;18(13):2515-21.
7. Sparber A, Bauer L, Curt G, et al. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 2000;27(4):623-30.
8. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18(13):2505-14.
9. Newton K, Buist D, Keenan N, Anderson L, LaCroix A. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol 2002;100(1):18-25.
10. Ganz P, Desmond K, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002; 94(1):39-49.
11. Emmons K, Kalkbrenner K, Klar N, et al. Behavioral risk factors among women presenting for genetic testing. Cancer Epidemiol Biomarkers Prev 2000;9(89):89-93.
12. Lerman C, Hughes C, Croyle R, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000; 31:75-80.
13. DiGianni L, Kim H, Emmons K, et al. Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev 2002;12(4):321-6.
14. Emmons K, Marcus B, Linnan L. Mechanisms in multiple risk factor interventions: smoking, physical activity, and dietary fat intake among manufacturing workers. Prev Med 1994;23:481-9.
15. Rossi J, Blais L, Weinstock M. The Rhode Island sun smart project: skin cancer prevention reaches the beaches. Am J Public Health 1994;84:672-4.
16. Burstein HJ, Gelber S, Guadagnol E, Weeks J. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340(22):1733-9.
17. Derogatis L, Spencer P. Brief Symptom Inventory (BSI): administration, scoring, and procedures manual. Baltimore (Maryland): Clinical Psychometric Research; 1992.
18. SAS Institute. SAS/STAT user's guide, version 6. Cary (North Carolina): 1990.
19. vanBelle G, Fisher L. Biostatistics: a methodology for the health sciences. New York: Wiley; 1993.
20. Schwartz M, Peshkin B, Hughes C, et al. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002; 20(2):514-20.
21. Schwartz M, Kaufman E, Peshkin B, et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003;21(21):4034-41.
22. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2001. Washington (District of Columbia); 2001.
23. U.S. Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Washington (District of Columbia): Centers for Disease Control and Prevention; 1996.
24. Centers for Disease Control and Prevention. Preventing skin cancer: findings of the task force on community preventive services on reducing exposure to ultraviolet light and counseling to prevent skin cancer: recommendations and rationale of the U.S. Preventive Services Task Force. Washington (District of Columbia): MMWR; 2003.
25. King M, Marks J, Mandell J, The NY Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302(24):643-6.
26. Carpenter C, Ross R. Effect of family history, obesity, and exercise on breast cancer risk among postmenopausal women. Int J Cancer 2003;106:96-102.
27. Willett W. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 2001;10(1):3-8.
28. Van Patten C, Olivotto I, Chambers G, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20(6):1449-55.
29. Quella S, Loprinzi C, Barton D, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18(5):1068-74.
30. MacGregor C, Canney P, Patterson G, McDonald R, Paul J. A randomized double-blinded controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41(5):708-14.
31. Fung T, Hu F, Holmes M, et al. Dietary patterns and the risk of postmenopausal breast cancer. Int J Cancer 2005;116:116-21.
32. Narod S, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23(8):1656-63.
33. Meijers-Heijboer E, Verhoog L, Brekelmans C, et al. Presymptomatic DNA testing and prophylactic surgery in families with A BRCA1 or BRCA2 mutation. Lancet 2000;355:2015-20.
34. Botkin J, Smith K, Croyle R, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 2003;118A:201-9.
35. US Dept of Health and Human Services Office of Disease Prevention and Health Promotion, National Center for Health Statistics. Healthy people 2010. Hyattsville (Maryland): US; 2005.
36. Lovegrove E, Rumsey N, Harcourt D, Cawthorn S. Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer. Psychooncology 2000;9(3):193-202.
37. Kash K, Holland J, Halper M, Miller D. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992;84:24-30.
38. Carlson L, Speca M, Patel K, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004;29:448-74.
39. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA 1996;275(24):1885-92.
40. Jacobson JS, Workman SB, Kronenberg F. Research on complementary and alternative therapies for cancer: issues and methodological considerations. J Am Med Womens Assoc 1999;54(4):177-83.